Poongjeon Pharmacy Confirms 2 Billion KRW Third-Party Rights Offering Resulting in 9% Dilution

Poongjeon Pharmacy disclosed the results of a third-party allotment rights offering completed with payment on June 30, 2026.
A total of 796,812 new common shares were issued for approximately 2 billion KRW, resulting in dilution of about 9.0% relative to the existing 8,840,635 shares outstanding.
The issue price of 2,510 KRW represents a 13% discount to the reference price of 2,885 KRW, and the new shares are subject to a one-year lock-up agreement with Korea Securities Depository.
The specific use of proceeds was not disclosed, but the third-party allotment structure suggests strategic financing or ownership stabilization purposes.
[AI Summary]Poongjeon Pharmacy's completion of a 2 billion KRW third-party rights offering has diluted existing shareholders by approximately 9%. While the discounted issue price and one-year lock-up mitigate short-term downside, uncertainty around the use of funds remains a key investment risk.